Anton Rx Report

The word on the street is that CVS has acquired US Bioservices from AmerisourceBergen….. and it seems that CVS is treating it as a closely

The topic of the article below did not get much coverage in the media….. and that is unfortunate….. the issue should be important to all

Specialty pharmacies have, presumably, been preparing to implement new workflows to accommodate the anticipated January launch of new CMS regulations related to copay accumulator transactions.

The FDA recently approved a new form of therapy for ALS. Normally, a new form is not big news, but, for this therapy, it may

The FDA recently approved the fourth pegfilgrastim biosimilar referencing Neulasta, Fylnetra (pegfilgrastim-pbbk) from Amneal Pharmaceuticals. Fylnetra is a leukocyte growth factor indicated to decrease the

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely

Now here’s something ya don’t see every day!A drug approved within the last year being yanked from the market. This week, the FDA pulled approval

Back in February we sent a report detailing an innovative network approach to alternate site / home infusion and it seems to be a topic

The FDA this week issued final guidance related to the importation of drugs from Canada. Importation was passed late last year but many questions remained unresolved. 

A significant number of specialty pharmacies have contracted as a 340b dispensing pharmacy often for multiple ‘program eligible’ hospitals. As most know, manufacturers have recently